A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in...

Area of Science:

• Hematology
• Cardiology
• Pharmacology

Background:

• Thalassemia major patients face fatal cardiomyopathy due to iron overload.
• Iron chelation therapy is standard but may not fully prevent cardiac iron accumulation.
• Calcium channel blockers are being investigated for their potential to reduce iron loading.

Purpose of the Study:

• To evaluate the efficacy and safety of adding amlodipine to standard iron chelators in reducing iron overload in thalassemia major.
• To assess the impact of combination therapy on cardiac and hepatic iron levels.
• To determine changes in serum ferritin levels and adverse effects.

Main Methods:

• A 1-year, randomized, controlled, single-center trial involving 56 thalassemia major patients.
• Patients were randomized to receive either iron chelator plus amlodipine (combined group) or iron chelator alone (control group).
• Iron content was assessed using heart and liver T2* magnetic resonance imaging, along with serum ferritin measurements.

Main Results:

• The combined group showed significant improvement in myocardial T2* values (P < .05), indicating reduced cardiac iron.
• No significant improvement was observed in hepatic T2* values in either group (P = .2).
• Both groups experienced significant reductions in serum ferritin levels, with mild gastrointestinal upset being the most common side effect.

Conclusions:

• Amlodipine addition to iron chelators offers a beneficial effect in reducing cardiac iron loading in thalassemia major.
• The combination therapy appears safe and effective for managing iron overload in this patient population.
• Further research may explore long-term cardiac benefits and optimal dosing strategies.